Système complémentaire

<p>Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5</p>

<p>PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50</p>

JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor.

Avacopan (CCX168) is a C5aR antagonist with selective and oral activity. Avacopan can be used to treat ANCA-related vasculitis. Cost-effective and quality-assured.

Leukadherin-1 boosts CD11b/CD18 adhesion, lowers leukocyte movement, cuts inflammation.

BCX 1470 inhibits factor D & C1s better than trypsin (IC50: 96 nM & 1.6 nM, 3.4- & 200-fold).

<p>Compstatin, a cyclic tridecapeptide, which was originally discovered from phage-display libraries, is a highly potent and selective C3 inhibitor.</p>

<p>ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist.Cost-effective and quality-assured.</p>

Compstatin control peptide acetate is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

<p>Danicopan (ACH-4471), an oral factor D inhibitor, binds strongly (Kd 0.54 nM) and may treat PNH and aHUS.</p>

Complement factor D-IN-2 is an inhibitor of Complement factor D and reduces the excessive activation of complement factor D.

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM.

Complement C5 Protein, Human, Recombinant (Complement C5a) is expressed in E.

AMY-101 acetate (Cp40 acetate) is a peptide, an inhibitor of C3 Complement in gingivitis and periodontitis, reduces inflammation and lowers MMP-8 and MMP-9.

<p>Expression system: E. coli&lt;br&gt;Length: 306-351, Partial&lt;br&gt;Activity: Not Tested</p>

<p>Complement C8a Protein, Human, Recombinant (His) is expressed in E. coli.</p>

<p>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.</p>

<p>A positive regulator of the alternate pathway of complement.</p>

Complement C3 Protein, Mouse, Recombinant (His & SUMO) is expressed in E.

C8 is a constituent of the membrane attack complex.

<p>Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate</p>

Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process.

Complement C3 Protein, Bovine, Recombinant (His & SUMO) is expressed in E.

Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate

<p>C1QA Protein, Human, Recombinant (His &amp; Myc) is expressed in E. coli.</p>

<p>Expression system: E. coli&lt;br&gt;Length: 41-234, Partial&lt;br&gt;Activity: Not Tested</p>

A positive regulator of the alternate pathway of complement.

<p>C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system.</p>

<p>Complement factor I Protein, Rat, Recombinant (His &amp; Myc) is expressed in Baculovirus insect cells with N-10xHis and C-Myc tag.</p>

<p>Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of</p>

<p>May regulate the number of excitatory synapses that are formed on hippocampus neurons.</p>

<p>Complement C4-B Protein, Human, Recombinant (His &amp; SUMO) is expressed in E. coli.</p>

May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses.

<p>Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.</p>

<p>Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.</p>

<p>Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway.</p>

C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system.

Expression system: E. coli<br>Length: 306-351, Partial<br>Activity: Not Tested

Complement C5 Protein, Rat, Recombinant (His & Myc) is expressed in E.

C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system.

Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb.

<p>Crovalimab (SKY59; RO7112689) is an humanised monoclonal antibody that binds to complement C5 , paroxysmal nocturnal haemoglobinuria (PNH).</p>

<p>Gefurulimab (ALXN-1720) is a bispecific antibody derived from humans, targeting complement C5 and albumin.</p>

<p>Riliprubart (SAR445088) is a humanized monoclonal antibody that acts as an anti-C1s inhibitor in the proximal part of the classical complement system. It selectively targets activated C1s, inhibiting its enzymatic activity on substrates C4 and C2, thereby preventing the formation of the classical pathway C3 convertase, C4b2a [1].</p>

<p>Empasiprubart (anti-C2 mAb) inhibits classical &amp; lectin complement pathways upstream of C3, showing efficacy in autoimmune models.</p>

BCX 1470 inhibits the esterolytic activity of factor D and C1s (IC50: 96 nM and 1.6 nM), 3.4- and 200-fold better than that of trypsin, respectively.

FD-IN-1 is an orally active Factor D (FD) inhibitor (IC50=12 nM), inhibits Factor XIa and Tryptase β2 with IC50 values of 7.7 and 6.5 μM, respectively.

Isocyclosporin A is a rearranged degradation product. It is formed by acid treatment of cyclosporin A under aqueous and non-aqueous conditions.

NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist.

<p>C5aR-IN-2, a potent C5aR inhibitor, shows promise for researching inflammatory diseases.</p>

<p>C3a Receptor Agonist activates C3aRs, inhibits neutrophil mobilization in ischemia, and promotes neural progenitor differentiation.</p>

NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

EG00229 blocks VEGF-A/NRP1 binding, IC50 of 3 μM; doesn't affect VEGFR-1/2. It's an NRP1 antagonist.

EG01377 is a NRP1 antagonist with antiangiogenic, antimigratory, and antitumor activity, Kd 1.32 μM, IC50s 609 nM for NRP1-a1/b1, inactive on NRP2.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

C5aR-IN-1, a potent C5aR inhibitor, may aid in researching autoimmune and inflammatory diseases.

W-54011: potent non-peptide C5a receptor blocker; binds 125I-C5a (Ki=2.2nM); stops Ca2+ movement, chemotaxis, ROS in neutrophils (IC50=1.6-3.1nM).

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. Cost-effective and quality-assured.

<p>Pelecopan (BCX9930), an oral complement factor D inhibitor, prevents hemolysis in PNH (IC50=14.3 nM).</p>

Factor B-IN-4 is a potent inhibitor (IC50: 1 μM) of complement factor B. Factor B-IN-4 can be used to study inflammatory and immune-related diseases.

Factor B-IN-3 is a potent inhibitor of complement factor B. Factor B-IN-3 can be used to study inflammatory and immune-related diseases.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM, demonstrating an inhibition activity on rabbit erythrocyte hemolysis with an IC50 of 41 nM. It possesses excellent pharmacokinetic and pharmacodynamic properties.

C5aR-IN-3, a potent C5aR inhibitor, may treat autoimmune and inflammatory diseases.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

<p>TLQP-21 TFA （TLQP-21 Trifluoroacetate） 是一种 VGF 衍生肽，可通过结合后折叠机制激活C3aR1 受体。</p>

<p>TLQP-21 TFA is a VGF-derived peptide, C3aR1 agonist (mouse EC50: 10.3μM; human EC50: 68.8μM), that raises intracellular Ca2+ for nociception research.</p>